April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Conversion to aflibercept for patients with neovascular age-related macular degeneration who were refractory to ranibizumab treatment
Author Affiliations & Notes
  • Yu Kawashima
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Akio Oishi
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Masahiro Miyake
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Munemitsu Yoshikawa
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Ayako Takahashi
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Naoko Ueda
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Hiroshi Tamura
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Kenji Yamashiro
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Akitaka Tsujikawa
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Nagahisa Yoshimura
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Footnotes
    Commercial Relationships Yu Kawashima, None; Akio Oishi, None; Masahiro Miyake, None; Munemitsu Yoshikawa, None; Ayako Takahashi, None; Naoko Ueda, None; Hiroshi Tamura, None; Kenji Yamashiro, None; Akitaka Tsujikawa, None; Nagahisa Yoshimura, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3952. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yu Kawashima, Akio Oishi, Masahiro Miyake, Munemitsu Yoshikawa, Ayako Takahashi, Naoko Ueda, Hiroshi Tamura, Kenji Yamashiro, Akitaka Tsujikawa, Nagahisa Yoshimura, ; Conversion to aflibercept for patients with neovascular age-related macular degeneration who were refractory to ranibizumab treatment. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3952.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the visual and anatomic outcomes of patients with neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) who were refractory to ranibizumab and were converted to aflibercept.

Methods: We included the patients with AMD or PCV who were treated with ranibizumab for longer than 6 months and showed recurrent or residual exudative changes after consecutive 3 times of injections. All these patients were switched to 3 monthly and following bi-monthly injections of aflibercept (2.0mg). We investigated the changes in visual acuity, central foveal thickness, and the height of the subfoveal pigment epithelial detachment as determined with optical coherence tomography after 6 months.

Results: Forty-one eyes of 41 patients were included. There were 15 AMD patients and 26 PCV patients. The average number of previous injections with anti-vascular endothelial growth factor agents was 10.9 ± 8.3 times. At the 6-months follow-up, mean visual acuity and central foveal thickness improved significantly from 0.40 ± 0.36 logMAR unit and 138.1 ± 78.7 μm at baseline to 0.34 ± 0.39 logMAR unit (P < 0.001) and 130.7 ± 55.9 μm (P = 0.007), respectively. Maximum height of the pigment epithelial detachment improved significantly from 134.5 ± 127.3 μm to 102.5 ± 125.8 μm (P < 0.001). In addition, the improvement of visual acuity was significantly better in patients with PCV than in patients with AMD (-0.09 ± 0.14 vs. 0.00 ± 0.10, P = 0.021).

Conclusions: Switching to aflibercept is beneficial for cases with exudative AMD and PCV who were refractory to ranibizumab. The beneficial effect of switching treatment might be greater in PCV than in typical AMD.

Keywords: 412 age-related macular degeneration • 550 imaging/image analysis: clinical • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×